What they are saying about Rheomuco
Pr. Isabelle Sermet-Gaudelus, Researcher in the Department of Pediatric Pneumology and Allergology, Necker Institute, Paris
Working on the sputum of the young patients is complicated because of the volumes available. However, not all children have the same quality of mucus and the same degree of inflammation. The Rheonova solution can be a tool to assess the progressive risk of the disease. With a pediatric cohort, a prospective longitudinal study should validate the potential and see the response of patients to the CFTR modulator based on rheological characteristics.
William Poncin, Respiratory physiotherapist at cliniques universitaires Saint-Luc
Ensuring an optimal bronchial clearance is one of the essential roles of physiotherapy in respiratory diseases such as Cystic fibrosis. However, fulfilling this objective is not always easy, due to the unfavorable rheological properties of the sputum of CF patients. It is therefore of practical interest for the physiotherapist to understand sputum rheology and to characterize the impact of the diverse clearance techniques on the viscoelastic properties of sputum. This would help the physiotherapist to select the most appropriate technique or to refine a specific therapeutic method so as to optimize the bronchial clearance.
Dr. Annie Viallat, Researcher at Marseille Interdisciplinary center of nanoscience
The viscoelasticity of bronchial secretions is a relevant indicator that was not taken into account until now. Its acquisition in few minutes by Rheomuco should facilitate research and allow to know more about the different factors and the molecules influencing it.